Genetic modification of ex-vivo expanded stem cells for clinical application

Reeva Aggarwal, Vincent J Pompili, Hiranmoy Das

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Stem cell therapy is currently considered as an important regime for repairing, replacing or enhancing the biological functions of the damaged tissues. Among adult stem cells, hematopoietic stem cells (HSCs) are commonly used for cure of hematological disorders. However, the number of HSCs obtained from sources like bone marrow, peripheral or umbilical cord blood is not sufficient for routine clinical application. Thus, ex-vivo expansion of HSCs becomes critically important. Ex-vivo culture and expansion of stem cells are challenging, as stem cells differentiate in culture rather than self-renew. Lack of clarity about the factors responsible for quiescence and differentiation of HSCs, investigators struggled to optimize conditions for ex vivo expansion. As we understand better, various strategies can be incorporated to mimic in vivo conditions for successful expansion of stem cells. However, characterization and biological functionality should also be tested for expanded stem cells prior to clinical application. To treat ischemia by enhancing therapeutic angiogenesis and neo-vascularization, the role of genetic modification of HSCs with pro-angiogenic factors is the focus of this review.

Original languageEnglish (US)
Pages (from-to)854-871
Number of pages18
JournalFrontiers in Bioscience
Volume15
Issue number3
DOIs
StatePublished - Jun 1 2010

Fingerprint

Hematopoietic Stem Cells
Stem cells
Stem Cells
Adult Stem Cells
Angiogenesis Inducing Agents
Cell- and Tissue-Based Therapy
Fetal Blood
Cell culture
Ischemia
Bone Marrow
Research Personnel
Bone
Blood
Tissue
Therapeutics

Keywords

  • Ex-vivo
  • Expansion
  • Genetic modification
  • Hematopoietic stem cells
  • Ischemia
  • Neo-vascularization
  • Niche
  • Non-viral
  • Pro-angiogenic factors
  • Review
  • Transduction
  • Virus

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Genetic modification of ex-vivo expanded stem cells for clinical application. / Aggarwal, Reeva; Pompili, Vincent J; Das, Hiranmoy.

In: Frontiers in Bioscience, Vol. 15, No. 3, 01.06.2010, p. 854-871.

Research output: Contribution to journalArticle

Aggarwal, Reeva ; Pompili, Vincent J ; Das, Hiranmoy. / Genetic modification of ex-vivo expanded stem cells for clinical application. In: Frontiers in Bioscience. 2010 ; Vol. 15, No. 3. pp. 854-871.
@article{1c927fe2be3244e3bb8b952e0243bf32,
title = "Genetic modification of ex-vivo expanded stem cells for clinical application",
abstract = "Stem cell therapy is currently considered as an important regime for repairing, replacing or enhancing the biological functions of the damaged tissues. Among adult stem cells, hematopoietic stem cells (HSCs) are commonly used for cure of hematological disorders. However, the number of HSCs obtained from sources like bone marrow, peripheral or umbilical cord blood is not sufficient for routine clinical application. Thus, ex-vivo expansion of HSCs becomes critically important. Ex-vivo culture and expansion of stem cells are challenging, as stem cells differentiate in culture rather than self-renew. Lack of clarity about the factors responsible for quiescence and differentiation of HSCs, investigators struggled to optimize conditions for ex vivo expansion. As we understand better, various strategies can be incorporated to mimic in vivo conditions for successful expansion of stem cells. However, characterization and biological functionality should also be tested for expanded stem cells prior to clinical application. To treat ischemia by enhancing therapeutic angiogenesis and neo-vascularization, the role of genetic modification of HSCs with pro-angiogenic factors is the focus of this review.",
keywords = "Ex-vivo, Expansion, Genetic modification, Hematopoietic stem cells, Ischemia, Neo-vascularization, Niche, Non-viral, Pro-angiogenic factors, Review, Transduction, Virus",
author = "Reeva Aggarwal and Pompili, {Vincent J} and Hiranmoy Das",
year = "2010",
month = "6",
day = "1",
doi = "10.2741/3650",
language = "English (US)",
volume = "15",
pages = "854--871",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "3",

}

TY - JOUR

T1 - Genetic modification of ex-vivo expanded stem cells for clinical application

AU - Aggarwal, Reeva

AU - Pompili, Vincent J

AU - Das, Hiranmoy

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Stem cell therapy is currently considered as an important regime for repairing, replacing or enhancing the biological functions of the damaged tissues. Among adult stem cells, hematopoietic stem cells (HSCs) are commonly used for cure of hematological disorders. However, the number of HSCs obtained from sources like bone marrow, peripheral or umbilical cord blood is not sufficient for routine clinical application. Thus, ex-vivo expansion of HSCs becomes critically important. Ex-vivo culture and expansion of stem cells are challenging, as stem cells differentiate in culture rather than self-renew. Lack of clarity about the factors responsible for quiescence and differentiation of HSCs, investigators struggled to optimize conditions for ex vivo expansion. As we understand better, various strategies can be incorporated to mimic in vivo conditions for successful expansion of stem cells. However, characterization and biological functionality should also be tested for expanded stem cells prior to clinical application. To treat ischemia by enhancing therapeutic angiogenesis and neo-vascularization, the role of genetic modification of HSCs with pro-angiogenic factors is the focus of this review.

AB - Stem cell therapy is currently considered as an important regime for repairing, replacing or enhancing the biological functions of the damaged tissues. Among adult stem cells, hematopoietic stem cells (HSCs) are commonly used for cure of hematological disorders. However, the number of HSCs obtained from sources like bone marrow, peripheral or umbilical cord blood is not sufficient for routine clinical application. Thus, ex-vivo expansion of HSCs becomes critically important. Ex-vivo culture and expansion of stem cells are challenging, as stem cells differentiate in culture rather than self-renew. Lack of clarity about the factors responsible for quiescence and differentiation of HSCs, investigators struggled to optimize conditions for ex vivo expansion. As we understand better, various strategies can be incorporated to mimic in vivo conditions for successful expansion of stem cells. However, characterization and biological functionality should also be tested for expanded stem cells prior to clinical application. To treat ischemia by enhancing therapeutic angiogenesis and neo-vascularization, the role of genetic modification of HSCs with pro-angiogenic factors is the focus of this review.

KW - Ex-vivo

KW - Expansion

KW - Genetic modification

KW - Hematopoietic stem cells

KW - Ischemia

KW - Neo-vascularization

KW - Niche

KW - Non-viral

KW - Pro-angiogenic factors

KW - Review

KW - Transduction

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=77956635117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956635117&partnerID=8YFLogxK

U2 - 10.2741/3650

DO - 10.2741/3650

M3 - Article

VL - 15

SP - 854

EP - 871

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - 3

ER -